How fast does insulin aspart work?

It has a faster onset and shorter duration than regular human insulin because it self-associates less, so it is taken close to mealtimes to cover the post-meal glucose rise.

What is faster-acting insulin aspart (Fiasp)?

It is a formulation of aspart with added excipients for even quicker absorption. A meta-analysis of randomized trials found it further lowers post-meal glucose compared with standard aspart.

What is the biggest safety concern with insulin aspart?

Hypoglycaemia, which can be severe, is the main risk; weight gain and injection-site reactions also occur. Doses must be individualised and supervised by a clinician.

Can insulin aspart be swapped for another insulin?

Not without clinician guidance. Insulin products differ in timing and strength, and switching or mixing them on your own can cause dangerous glucose swings.

EMA-approvedaka NovoLog, NovoRapid, Fiasp

Insulin aspart — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Insulin aspart (also known as NovoLog) is a peptide catalogued under Hormones & Metabolic (Rapid-acting insulin analogue). It is described as: Insulin receptor agonist. Documented context: Diabetes mellitus. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Insulin aspart?

Insulin aspart (brand names NovoLog in the US and NovoRapid in Europe) is a rapid-acting mealtime (bolus) human insulin analog approved by the FDA and EMA for type 1 and type 2 diabetes in adults and children.

It is a widely used prescription drug backed by randomized controlled trials and meta-analyses in humans; a faster-absorbed formulation (faster aspart, Fiasp) is also approved.

It is not a research chemical.

How does Insulin aspart work?

Substituting proline at position B28 with aspartic acid reduces hexamer formation, allowing quicker subcutaneous absorption than regular human insulin.

The result is a faster onset and shorter action that better covers the post-meal glucose rise.

What does the research say about Insulin aspart?

In a randomized controlled trial in type 1 diabetes, insulin aspart improved long-term blood glucose control (HbA1c) compared with regular human insulin. ^[1]
A meta-analysis of basal-bolus regimens found insulin aspart improved glycaemic control versus regular human insulin, with better postprandial glucose. ^[2]
A meta-analysis reported that faster-acting insulin aspart further reduced postprandial glucose compared with conventional insulin aspart. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial — Home PD et al., Diabetic Medicine 2000. (Randomized controlled trial)
[2] Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus — Heller S et al., Journal of Diabetes 2013. (Meta-analysis)
[3] Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials — Pal R et al., Diabetic Medicine 2021. (Meta-analysis of RCTs)
[4] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. (Systematic review and meta-analysis)
[5] Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus — Reynolds NA et al., Drugs 2004. (Narrative review)
[6] Safety of insulin analogs during pregnancy: a meta-analysis — Lv S et al., Archives of Gynecology and Obstetrics 2015. (Meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In practice, insulin aspart is injected subcutaneously immediately before or just after a meal as the bolus insulin, or delivered by pump.

This is context only and not dosing guidance; only a prescribing clinician can determine an appropriate regimen.

Side effects & safety profile

As with all mealtime insulins, hypoglycaemia is the main and potentially severe risk, especially with missed meals, exercise or dosing errors.

Weight gain, injection-site reactions, lipohypertrophy and rare hypersensitivity can also occur.

Dosing must be individualised by a clinician, and aspart should never be interchanged or mixed with other insulin products without professional guidance.

Stacking & combinations

It is usually paired with a long-acting basal insulin as part of basal-bolus therapy under medical supervision, not combined with other agents on a self-directed basis.

Finding Insulin aspart vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. It is an FDA- and EMA-approved prescription insulin analog (NovoLog/NovoRapid) for type 1 and type 2 diabetes; a faster-absorbed version (Fiasp) is also approved. It is not a research-only compound.

References

[1] Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial — Home PD et al., Diabetic Medicine 2000. PMID: 11131100. View sourceStudy: Randomized controlled trialInsulin aspart improved long-term glycaemic control versus regular human insulin in type 1 diabetes.
[2] Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus — Heller S et al., Journal of Diabetes 2013. PMID: 23586846. View sourceStudy: Meta-analysisAspart in a basal-bolus regimen improved glycaemic control, including postprandial glucose, versus regular human insulin.
[3] Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials — Pal R et al., Diabetic Medicine 2021. PMID: 33420727. View sourceStudy: Meta-analysis of RCTsFaster-acting insulin aspart reduced postprandial glucose compared with conventional insulin aspart.
[4] Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis — Melo KFS et al., Diabetology and Metabolic Syndrome 2019. PMID: 30622653. View sourceStudy: Systematic review and meta-analysisRapid-acting analogues improved postprandial glucose versus regular human insulin in type 1 diabetes.
[5] Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus — Reynolds NA et al., Drugs 2004. PMID: 15329046. View sourceStudy: Narrative reviewReviewed evidence that aspart improves postprandial control with a hypoglycaemia profile comparable to or better than regular human insulin.
[6] Safety of insulin analogs during pregnancy: a meta-analysis — Lv S et al., Archives of Gynecology and Obstetrics 2015. PMID: 25855052. View sourceStudy: Meta-analysisInsulin analogues including aspart showed a safety profile broadly comparable to human insulin in pregnancy.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.